U.S. Markets close in 5 hrs 55 mins
  • S&P 500

    4,182.80
    +37.61 (+0.91%)
     
  • Dow 30

    33,084.74
    +281.27 (+0.86%)
     
  • Nasdaq

    12,840.72
    +183.16 (+1.45%)
     
  • Russell 2000

    1,949.71
    +27.88 (+1.45%)
     
  • Crude Oil

    89.14
    +0.13 (+0.15%)
     
  • Gold

    1,799.80
    +8.60 (+0.48%)
     
  • Silver

    20.44
    +0.60 (+3.01%)
     
  • EUR/USD

    1.0201
    +0.0014 (+0.1326%)
     
  • 10-Yr Bond

    2.7830
    -0.0570 (-2.01%)
     
  • Vix

    21.50
    +0.35 (+1.65%)
     
  • GBP/USD

    1.2120
    +0.0049 (+0.4072%)
     
  • USD/JPY

    134.4360
    -0.5340 (-0.3956%)
     
  • BTC-USD

    24,171.68
    +1,012.08 (+4.37%)
     
  • CMC Crypto 200

    564.54
    +21.66 (+3.99%)
     
  • FTSE 100

    7,507.47
    +67.73 (+0.91%)
     
  • Nikkei 225

    28,249.24
    +73.37 (+0.26%)
     

Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WALTHAM, Mass., May 02, 2022--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2022 financial results on Wednesday, May 4, 2022.

In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 8:00 AM ET on Wednesday, May 4, 2022, to discuss the Company’s financial results and provide a corporate update.

The conference call may be accessed by dialing (877) 270-2148 (domestic) or (412) 902-6510 (international). A webcast of the conference call will be available in the "Events and Presentations" page in the "Investors" section of the Company’s website at https://investors.deciphera.com/events-presentations. The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005060/en/

Contacts

Investor Relations:
Maghan Meyers
Argot Partners
Deciphera@argotpartners.com
212-600-1902

Media:
David Rosen
Argot Partners
David.Rosen@argotpartners.com
212-600-1902